XomeXBio SRL
4.0 FTEXomeXBio reported total assets of €3.50m at the end of the 2025 financial year (annual accounts filed with the NBB on 15 Jul 2026), with 4 full-time equivalents.
The score of XomeXBio shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2023 → 2025: Equity +1028 % Total assets +89 % Headcount (avg FTE) +3900 %
Accounts of the company itself (not consolidated).
The full file covers 3 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
XomeXBio's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 15 Jul 2026
- Year ended 31 Dec 2024filed on 04 Sep 2025
- Year ended 31 Dec 2023filed on 30 Aug 2024
XomeXBio's financial analysis
- Solvency30.2%sector median: 57.9%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of XomeXBio
XomeXBio's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0801.880.687
- VAT number
- BE0801880687
- Peppol
- Registered · 0208:0801880687 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 17 May 2023
- Registered office
- 6041 Charleroi
- Size
- Micro · 4.0 FTE
- Latest accounts
- 2025 · filed on 15 Jul 2026
- Activity
- Research and experimental development on biotechnology (NACE 72101)
XomeXBio (SRL) has been based in Charleroi since 2023, active in: research and experimental development on biotechnology. For 2025, it reports a net loss of 528,922 € and equity of €1.06m; its revenue is not published. With 4.0 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 30.2%, below the median of its sector (57.9%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to XomeXBio
Companies in the same business, of comparable size and area, outside its group.
- Wishbone Research and experimental development on natural sciences and engineering Flémalle · balance sheet €3.39m
- Genflow Biosciences Research and experimental development on natural sciences and engineering Charleroi · balance sheet €3.74m
- ExeVir Bio Research and experimental development on natural sciences and engineering Ghent · balance sheet €3.76m
- Tanai Therapeutics Research and experimental development on natural sciences and engineering Ghent · balance sheet €3.87m
- Ipratech Research and experimental development on natural sciences and engineering Charleroi · balance sheet €4.29m
- Bio-Sourcing Research and experimental development on natural sciences and engineering Liège · balance sheet €6.59m
- Olfadog Biotech Research and experimental development on natural sciences and engineering Waterloo · balance sheet €1.80m
- Amyl Therapeutics Research and experimental development on natural sciences and engineering Liège · balance sheet €7.02m
Frequently asked questions about XomeXBio
What is the revenue of XomeXBio?
XomeXBio files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of XomeXBio?
In Belgium, the VAT number is the company number prefixed with BE: BE0801880687 for XomeXBio, if the company is VAT-registered. Its company number (CBE) is 0801.880.687.
Where is the registered office of XomeXBio?
According to the CBE register, the registered office of XomeXBio is in 6041 Charleroi.
What is the equity of XomeXBio?
At the close of the 2025 financial year, the equity of XomeXBio amounts to 1,056,078 €, a solvency of 30.2% of total assets.
How many people work at XomeXBio?
4.0 full-time equivalents on average according to the 2025 social balance sheet.
Who manages XomeXBio?
The register lists 7 active mandates at XomeXBio. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of XomeXBio
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →